Author Index

Abuhijleh, A. L., 167
Algül, Ö., 71
Alonso, C., 283
Amo-Ochoa, P., 257
Argüelles, M. C. R., 295
Ascoli, F., 211
Atassi, G., 53
Atrian, S., 157

Bae, W., 201
Bakhtiar, R., 273
Bandwar, R. P., 1
Bauer, C., 129
Bentfrit, F., 53
Bergamaschi, G., 295
Berthon, G., 27
Betts, P. W., 177
Bigi, A., 45
Bonardi, A., 295
Bragadin, M., 75
Brothers, P. J., 215
Brumas, V., 27
Buss, J. L., 101

Capdevila, M., 157
Caravan, P., 109
Casella, L., 61
Chen, Y., 183
Chung, Y. K., 289
Ciancaglini, P., 123
Cojazzi, G., 45
Cols, N., 157

De Gioia, L., 17
Demertzis, M. A., 147
Denny, W. A., 215
Domopoulou, A., 147
Dung, N. H., 53

Egan, T. J., 137

Farkas, E., 85
Fazio, G., 251
Feroci, G., 251
Ferrari, R. P., 17, 61
Fini, A., 251
Fletcher, T. M., 239

Gelmini, L., 109
Ghibaudi, E. M., 17, 61
Glover, N., 109
Gonazàlez-Duarte, P., 157
Gonazàlez-Duarte, R., 157
González, V. M., 283
Guilbaud, N., 53
Gümüs, F., 71

Hasinoff, B. B., 101
Hefter, G. T., 225
Hop, C. E. C. A., 273
Hu, M.-F., 195

Jin, L., 79

Kiss, A., 85
Kovala-Demertzi, D., 147
Kumar, C. V., 177

Laurenti, E., 17, 61
Lee, Y. A., 289
Leonce, S., 53
Leone, F. A., 123
Leporati, E., 295
Leung, K. H., 273
Lippert, B., 85
Luo, Q.-H., 195

Marques, H., 137
Martin, R. B., 7
Marton, D., 75
Mavuso, W. W., 137
May, P. M., 225
Mazza, P., 295
McFadyen, W. D., 279
McNeill, J. H., 109
Mehra, R. K., 201
Miche, H., 27
Morgant, G., 53
Moro, L., 45

Nelson, D. J., 7
Nomiya, K., 39

Oda, M., 39
Oliva, B., 157
Orvig, C., 109

Palmer, H. R., 215
Panzavolta, S., 45
Papageorgiou, A., 147
Pelagatti, P., 295
Pelizzi, C., 295
Pelizzi, G., 295
Pérez, J. M., 283
Pierre, A., 53
Pizauro, J. M., 123
Prenzler, P. D., 279

0162-0134/97/$17.00
PII S0162-0134(97)00157-8

Rao, C. P., 1
Rickard, C. E. F., 215
Rico, S., 257
Ripamonti, A., 45
Romanello, M., 45
Romero-Isart, N., 157
Ross, D. C., 137
Roveri, N., 45
Rowatt, E., 235

Salmona, M., 17
Santucci, R., 211
Setyawati, I. A., 109
Shen, C.-Y., 195
Shen, M.-C., 195
Shen, X., 265
Shepherd, R. E., 183
Sohn, Y. S., 289
Sorensen, E. S., 235
Sóvágó, I., 85
Stearns, R. A., 273
Suarez, K. N., 45
Sudoh, T., 39

Tajima, Y., 93
Tan, W. B., 177
Tang, L. X., 265
Thormann, B., 85
Tian, Y., 117
Tran-Ho, L.-C., 225
Traversa, S., 17
Triffit, J., 235
Trindle, C., 7
Tsuda, K., 39

Valle, G., 147
Viess, A., 235
Viossant, B., 53

Walmsley, J. A., 239
Wang, A. H.-J., 129
Wang, H., 117
Wang, X., 7
Ware, D. C., 215
Williams, R. J. P., 235
Wilson, W. R., 215

Yang, J. L., 265
Yang, P., 79, 117
Yuen, V. G., 109

Zamora, F., 257
Zani, F., 295
Zhang, Z., 117
Zhao, C., 117
Zhou, Y., 109
Zuman, P., 251

Subject Index

Absorption band, 695-nm, heme(III)-met(80) axial bond in horse cytochrome *c*, 211
N-acetyl amino acids, solution eqilibria of palladium(II) complexes with nucleobases and, 85
2-Acetylpyridine N(4)-methyl, N(4)-ethyl adn N(4)-phenyl-thiosemicarbazones, palladium(II) complexes, 147
ADP and ATP, Al^{3+} complexation, 7
Aluminum
  Al^{3+} complexation, ADP and ATP, 7
  binding
    hydroxyapatite, 235
    protein and mineral components of bone and teeth, 235
Anionin channel, mitochondria interaction with trialkyltin (TAT) compounds, 75
Anions, inorganic, interaction with lactoperoxidase, 17
9-Anthracene methyl ammonium chloride, hexamminecobalt(III) chloride, sequence dependent cleavage of DNA, 177
Anthranilic acid, potential OH-inactivating ligand, 27
Antibiotics, undecaphosphotungstate, effects on β-lactam antibiotics on *Staphylococcus aureus*, 93
Anticonvulsants, copper(II) complexes with valproate with diimines, 167
Antimalarial drugs, quinoline, interaction with ferriprotoporphyrin IX, 137
Antimicrobial activity
  Ag(I)-N bonding compound, 39
  organotin complexes with pyrrole-2-carboxaldehyde monoacylhydrazones, 295
Antioxidant cardioprotective agents, dexrazoxane (ICRF-187), effects, 101
Antitumor activity
  cerium(IV)-mitoxantrone complex, 117
  cobalt(III) mixed-polypyridyl complex, 79
  (diamine)platinum(II) complexes of benzylmalonate derivatives, 289
  2,5-diphenyl-1,3,4-oxadiazole-derived palladium complexes, reactivity against nucleobase models, 257
  metformin platinum (IV) complex, 53
  palladium(II) complexes, 2-acetylpyridine N(4)-methyl, N(4)-ethyl adn N(4)-phenyl-thiosemicarbazones, 147
  in vitro and in vivo, synthesis and spectral studies, 147

Benzylmalonate derivatives, (diamine)platinum(II) complexes, 289
Berenil ligand, DNA binding of cytotoxic drug Pt-berenil, 283
Bile salts, iron(II) interaction, 251
Bis(kojato)oxovanadium(IV), insulin-mimetic properties, 109
Bis-tropolonato derivatives, cobalt(III) complexes, bidentate aliphatic nitrogen mustards, 215
Blood plasma, copper speciation, 225
Bones, aluminum binding to protein and mineral components, 235

Cadmium(II) binding, metallothioneins, 157
Calcium ions, effect on osseous plate alkaline phosphatase activity, 123
Cardioprotective agents, dexrazoxane (ICRF-187), effects, 101
Cerium(IV)-mitoxantrone complex, antitumor activity, 117
Chenodeoxycholate(CDC), iron(II) interaction, 251
Cholate(C), iron(II) interaction, 251
Cisplatin, Tris and Hepes reactions, 279
Cobalt(III)
  chiral cobalt(III)-amine complexes, stereospecific interactions with guanosine 5′-monophosphate, 239
  cobalt(III) bexaamine ion, DNA conformational changes, 129
  cobalt(III) complexes, bidentate aliphatic nitrogen mustards, 215
  cobalt(III) mixed-polypyridyl complex, synthesis and DNA binding studies, 79
Collagen posttranslational modifications, cortical and trabecular bone, chemical and structural characterization of mineral phase, 45
Copper
  copper speciation in blood plasma, 225
  copper(I) complexes
    macrocyclic bicopper(I) complexes, oxidative demethylation, 195
    thioamino acids, 225
  copper(II) complexes
    interactions with nonsteroidal antiinflammatory agents, 27
    valproate with diimines, 167
Cortical and trabecular bone, chemical and structural characterization of mineral phase, 45
Cytochrome *c*, heme(III)-met(80) axial bond, 211
Cytotoxins
  bis-tropolonato derivatives of cobalt(III) complexes of bidentate aliphatic nitrogen mustards, 215
  Pt-berenil, berenil ligand directs DNA binding, 283

Deoxycholate(DC), iron(II) interaction, 251
Dexrazoxane (ICRF-187), effects, 101
(Diamine)platinum(II) complexes of benzylmalonate derivatives, synthesis and antitumor activity, 289
cis-Diamminediaqua platinum(II), Tris and Hepes reactions, 279

0162-0134/97/$17.00
PII S0162-0134(97)00158-X

cis-Dichlorobis (5(6)-non/chlorosubstituted-2-hydroxymethyl-benzimidazole) platinum(II) complexes, DNA binding studies, 71
2,5-Diphenyl-1,3,4-oxadiazole, -derived palladium complexes, reactivity against nucleobase models, 257
DNA, sequence dependent cleavage, hexamminecobalt(III) chloride, 177
DNA binding studies
  cobalt(III) mixed-polypyridyl complex, 79
  cytotoxic drug Pt-berenil, 283
  platinum(II) complexes, 71
DNA conformational changes, cobalt(III) bexaamine ion, 129
DNA synthesis, cerium(IV)-mitoxantrone complex, 117
Dopamine *o*-semiquinone production, mechanism, 61
Doxorubicin cardioprotective agents, dexrazoxane (ICRF-187), effects, 101

Factor T, undecaphosphotungstate, effects on β-lactam antibiotics on *Staphylococcus aureus*, 93
Ferriprotoporphyrin IX, interaction with quinoline antimalarial drugs, 137

Genotoxicity, organotin complexes with pyrrole-2-carboxaldehyde monoacylhydrazones, 295
Glucose-lowering properties, vanadium compounds, 109
Glycocholate(GC), iron(II) interaction, 251
Guanosine 5′-monophosphate, stereospecific interactions, chiral cobalt(III)-amine complexes, 239

Heme adduct generation, 2,4,6-trinitrotoluene (TNT) in vitro reaction with human hemoglobin, 273
Heme(III)-met(80) axial bond, horse cytochrome *c*, 211
Hemoglobin, human, 2,4,6-trinitrotoluene (TNT) in vitro reaction, 273
Heterocyclic thiosemicarbazones, palladium(II) complexes, 2-acetylpyridine N(4)-methyl, N(4)-ethyl adn N(4)-phenyl-thiosemicarbazones, 147
Hexamminecobalt(III) chloride, sequence dependent cleavage of DNA, 177
Hydrolysis, metal-ion promotoed, dexrazoxane (ICRF-187), 101
Hydroxyapatite, aluminum binding, 235

Imidazole-bridged cobalt amine complexes, influence on conformation of oligonucleotides, 129
Inflammation, copper, 27
Inorganic anions, interaction with lactoperoxidase, 17
Insulin-mimetic properties, bis(kojato)oxovanadium(IV), 109
Iron complexes
  $iron^{2+}$-initiated lipid peroxidation, iron-chelators effects, 265
  iron(II) hydrolysis of dexrazoxane (ICRF-187), 101
  iron(II) interaction with bile salts, 251
  iron(III)
    ferriprotoporphyrin IX, interaction with quinoline antimalarial drugs, 137
    heme(III)-met(80) axial bond, horse cytochrome *c*, 211

Lactoperoxidase, interaction with inorganic anions, 17
Lipid peroxidation, iron-initiated, 265

Macrocyclic bicopper(I) complexes, oxidative demethylation, 195
Magnesium
  $magnesium^{2+}$, effect of calcium ions on osseous plate alkaline phosphatase activity, 123
  magnesium(II) hydrolysis of dexrazoxane (ICRF-187), 101
Membrane potential, mitochondria interaction with trialkyltin (TAT) compounds, 75
Metal-binding characteristics, phytochelatin analog $(Glu\text{-}Cys)_2$ Gly peptides, 201
Metal-ion promotoed hydrolysis, dexrazoxane (ICRF-187), 101
Metal polypyridyl coordination compounds, cobalt(III) mixed-polypyridyl complex, synthesis and DNA binding studies, 79
Metalloenzyme, osseous plate alkaline phosphatase activity, effect of calcium ions, 123
Metallothioneins, cadmium(II) binding, 157
Metformin platinum (IV) complex, synthesis and antitumor activity, 53
Mineral phase, chemical and structural characterization, cortical and trabecular bone, 45
Mitochondria, interaction of trialkyltin (TAT) compounds, 75
Mitoxantrone, cerium(IV)-mitoxantrone complex, antitumor activity, 117
Monooxygenases, mimicking, oxidative demethylation of macrocyclic bicopper(I) complexes, 195
Mustard complexes, *bis*-tropolonato derivatives of cobalt(III) complexes of bidentate aliphatic nitrogen mustards, 215

Neurotoxic agents, Al^{3+} complexation, ADP and ATP, 7
Nitric acid (NO) scavengers, ruthenium compounds, 183
Nonsteroidal antiinflammatory agents, copper(II) interactions, 27
Nucleic acids, xobalt(III) bexaamine ion induction of DNA conformational changes, 129
Nucleobase models, 2,5-diphenyl-1,3,4-oxadiazole-derived palladium complexes reactivity, 257

OH-inactivating ligand, anthranilic acid as potential, 27
Oligonucleotides, imidazole-bridged cobalt amine complexes effects, 129
Organotin, complexes with pyrrole-2-carboxaldehyde monoacylhydrazones, 295
Osseous plate alkaline phosphatase activity, effect of calcium ions, 123
Oxidative demethylation, macrocyclic bicopper(I) complexes, 195

Palladium complexes
  palladium(II)
    2-acetylpyridine N(4)-methyl, N(4)-ethyl adn N(4)-phenyl-thiosemicarbazones, 147
    solution eqilibria of ternary complexes, 85
  reactivity against nucleobase models, 257

Peptides, phytochelatin analog $(Glu\text{-}Cys)_2$ Gly, metal-binding characteristics, 201
Peroxidation, lipid, iron-initiated, 265
Phytochelatin analog $(Glu\text{-}Cys)_2$ Gly peptides, metal-binding characteristics, 201
Platinum complexes
  metformin platinum (IV) complex, synthesis and antitumor activity, 53
  platinum (II), *cis*-diamminediaqua platinum(II), Tris and Hepes reactions, 279
  platinum(II), (diamine)platinum(II) complexes of benzylmalonate derivatives, synthesis and antitumor activity, 289
Platinum(II) complexes, DNA binding studies, 71
Polymeric silver(I) imidazolate, antimicrobial activities, 39
Polypyridyl coordination compounds, transition metal, cobalt(III) mixed-polypyridyl complex, synthesis and DNA binding studies, 79
Protein, aluminum binding, 235
Pt-berenil, berenil ligand directs DNA binding, 283
pUC-18 DNA, vanadyl-monosaccharide complexes effects, 1
Pyrrole-2-carboxaldehyde monoacylhydrazones, organotin complexes, 295

Quinoline antimalarial drugs, interaction with ferriprotoporphyrin IX, 137
o-Quinone/*o*-semiquinone radical formation, kinetic studies, 61

Ruthenium compounds, ruthenium polyaminopolycarboxylates (Ru-pacs), 183

Saccharides, transition metal, vanadyl-monosaccharide complexes, effect on pUC-18 DNA, 1
Salts, dihydroxy bile, iron(II) interaction, 251
o-Semiquinone production, mechanism, 61
Septic shock, nitric acid (NO) scavengers, ruthenium compounds, 183
Silver, Ag(I)-N bonding compound, antimicrobial activities, 39
Staphylococcus aureus, undecaphosphotungstate, 93
Superoxide dismutase mimics, copper(II) complexes with valproate with diimines, 167
Surface accessibility analysis, cadmium(II) binding to metallothioneins, 157

Taurocholate(TC), iron(II) interaction, 251
Teeth, aluminum binding to protein and mineral components, 235
Ternary complexes, solution equilibria, 85
Tetrachloro(metformin)platinum(IV) dimethylsulfoxide solvate, crystal structure, 53
Thioamino acids, copper(I) complexation, 225
Toxicity, ruthenium compounds, 183
Trabecular bone, chemical and structural characterization of mineral phase, 45
Transition metal-nucleic acid chemistry, chiral cobalt(III)-amine complexes, stereospecific interactions with guanosine 5'-monophosphate, 239
Transition metal polypyridyl coordination compounds, cobalt(III) mixed-polypyridyl complex, synthesis and DNA binding studies, 79
Transition metal saccharides, vanadyl-monosaccharide complexes, effect on pUC-18 DNA, 1
Trialkyltin (TAT) compounds, new mechanism of interactions mitochondria, 75
2,4,6-Trinitrotoluene (TNT), in vitro reaction with human hemoglobin, 273
Tris and Hepes reactions, cisplatin and *cis*-diamminediaqua platinum(II), 279
Tyrosinase-catecholic substrates, in vitro model, 61

Undecaphosphotungstate, effects on β-lactam antibiotics on *Staphylococcus aureus*, 93

Vanadium compounds, glucose-lowering properties, 109
Vanadyl-monosaccharide complexes, effect on pUC-18 DNA, 1

Zinc complexes
  $zinc^{2+}$, effect of calcium ions on osseous plate alkaline phosphatase activity, 123
  zinc(II), hydrolysis of dexrazoxane (ICRF-187), 101